Stocktoria
Cibus, Inc. CBUS
Cibus, Inc. (CBUS) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $3.6M at a -3492.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.016 |
| Retained earnings / assets | -2.814 |
| EBIT / assets | -0.32 |
| Equity / liabilities | 0.077 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CBUS | Cibus, Inc. | 3/9 | -11.34 | — | — |
| SNES | SenesTech, Inc. | 4/9 | — | — | — |
| ZHJD | Intelligent Hotel Group Ltd. | 2/9 | — | — | — |
| AVD | AMERICAN VANGUARD CORP | 5/9 | 2.8 | — | -5.9% |
| UAN | CVR PARTNERS, LP | 7/9 | — | 11.7 | +15.4% |
| SMG | SCOTTS MIRACLE-GRO CO | 7/9 | 1.59 | 28 | -3.9% |
| CF | CF Industries Holdings, Inc. | 5/9 | 4.26 | — | +19.3% |
About Cibus, Inc.
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
FAQ
Is CBUS financially healthy?
Cibus, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CBUS pay a dividend?
No, Cibus, Inc. does not currently pay a dividend.
How profitable is CBUS?
In FY2025, Cibus, Inc. had a net margin of -3492.3% and a return on equity of -582.2%.
What is the analyst price target for CBUS?
The average Wall-Street price target for Cibus, Inc. is $14.67, about 676.0% above the recent price, from 3 analysts (consensus: buy).
Is CBUS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Cibus, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.